



HAL
open science

Mu opioid receptor, social behaviour and autism spectrum disorder: reward matters

Lucie P. Pellissier, Jorge Gandia-Sanchez, Thibaut Laboute, Jérôme A.J. Becker, Julie Le Merrer

► To cite this version:

Lucie P. Pellissier, Jorge Gandia-Sanchez, Thibaut Laboute, Jérôme A.J. Becker, Julie Le Merrer. Mu opioid receptor, social behaviour and autism spectrum disorder: reward matters. *British Journal of Pharmacology*, 2017, 175 (14), pp.1-41. 10.1111/bph.13808 . hal-01605908

HAL Id: hal-01605908

<https://hal.science/hal-01605908>

Submitted on 26 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

Mu opioid receptor, social behaviour and autism spectrum disorder: reward matters

Lucie P Pellissier*, Jorge Gandia*, Thibaut Laboute, Jerome AJ Becker, Julie Le Merrer

Physiologie de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247, Université de Tours Rabelais, INSERM, 37380 Nouzilly, France

* Contributed equally to this work

Running title: μ opioid receptor, social reward and autism

Corresponding author:

Julie Le Merrer, PhD

Physiologie de la Reproduction et des Comportements, INRA UMR-0085, CNRS UMR-7247, Université de Tours Rabelais, INSERM, 37380 Nouzilly, France

Email: julie.le-merrer@inra.fr

Abstract: 148 words

Main text: 4727 words

4 Figures

2 tables

Abstract

The endogenous opioid system is well known to relieve pain and underpin the rewarding properties of most drugs of abuse. Among opioid receptors, the μ opioid receptor (μ OR) mediates most of the analgesic and rewarding properties of opioids. Based on striking similarities between social distress, physical pain and opiate withdrawal, μ OR has been proposed to play a critical role in modulating social

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bph.13808

behaviour in humans and animals. This review summarizes experimental data demonstrating such role and proposes a novel model, the μ OR Balance Model, to account for μ OR contribution to the subtle regulation of social behaviour. Interestingly, μ OR null mice show behavioural deficits similar to these observed in patients with Autism Spectrum Disorders (ASD), including severe impairment in social interactions. Therefore, after a brief summary of recent evidence for blunted (social) reward processes in subjects with ASD, we review here arguments for altered μ OR function in this pathology.

Abbreviations:

ACC, anterior cingulate cortex; AMG, amygdala; ASD, autism spectrum disorders; AOB, accessory olfactory bulb; BNST, bed nucleus of stria terminalis; CC, cingulate cortex; CPu, caudate putamen; CRF, corticotropin-releasing factor; CSF, cerebrospinal fluid; CTAP, D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH₂; DAMGO, [D-Ala², N-MePhe⁴, Gly-ol⁵]-enkephalin; δ OR, δ opioid receptor; HPLC, high performance liquid chromatography; IC, insular cortex; GP, globus pallidus; GPCR, G-protein coupled receptor; κ OR, κ opioid receptor; LC, locus coeruleus; LS, lateral septum; MCC, middle cingulate cortex; μ OR, μ opioid receptor; NAc, nucleus accumbens; OFC, orbitofrontal cortex; PAG, periaqueductal gray matter; PCC, posterior cingulate cortex; PFC, medial prefrontal cortex; POA, preoptic area of hypothalamus; PVN, paraventricular nucleus of hypothalamus; RIA, radioimmunoassay; SAS, social avoidance systems; Th, thalamus; USV, ultrasound vocalisations; VTA: ventral tegmental area.

Social reward and social pain: overlapping neurobiological substrates

Depending on internal state and environment, interactions with conspecifics in humans and animals may be experienced as aversive or pleasurable. Indeed, individuals may either compete for resources, territory, mates, social status or parental care (Roughgarden, 2012) when these are scarce, or instead cooperate, play, mate, care for offspring, to ensure their survival and genetic legacy. In the latter

case, social interactions can elicit pleasure and euphoria (Fehr *et al.*, 2007; Neuhaus *et al.*, 2010; Trezza *et al.*, 2010) and accordingly activate brain regions belonging to the reward processing circuitry. Social interaction or craving for social connection activates the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) in humans (Fareri *et al.*, 2015; Inagaki *et al.*, 2016a; Kawamichi *et al.*, 2016). Conversely, activating reward regions such as ventral tegmental area (VTA) or dopaminergic raphe neurons in rodents promotes social interaction (Gunaydin *et al.*, 2014; Matthews *et al.*, 2016). Pleasure associated with social experience facilitates further social contact and may lead ultimately to the structuration of a social organization (Cacioppo *et al.*, 2011).

As a corollary of social organization, however, rejection by peers or loss of a close relative can be felt in social species as extremely painful, as much as an amputation (Parkes, 1975), and prolonged isolation elicits deleterious psychological and physical damages (Eisenberger *et al.*, 2016; Filipovic *et al.*, 2016). Remarkably, social rejection activates similar brain regions (anterior cingulate cortex – ACC, anterior insula, periaqueductal gray - PAG, amygdala) as physical pain (Eisenberger, 2012; Hsu *et al.*, 2013; Kross *et al.*, 2011; Papini *et al.*, 2015), suggesting that indeed rejected individuals experience “social pain”, which can be relived even more easily and more intensely than physical pain (Chen *et al.*, 2008). Importantly, social context, whether positive (such as images of loved ones in humans) or negative (rejection), can influence physical pain perception (Coudereau *et al.*, 1997; Defeudis *et al.*, 1976; Puglisi-Allegra *et al.*, 1983; Younger *et al.*, 2010). Together, these data suggest that affiliative and social behaviours have hijacked primary reward and pain systems to promote social interactions and avoid adverse social contexts (Nelson *et al.*, 1998).

At the neuronal level, multiple neurotransmitters modulate social behaviour, either facilitating or inhibiting social interactions. Remarkably, most of the former are well-known key players of the reward system, such as dopamine, noradrenaline, cannabinoids, oxytocin or opioids (Baribeau *et al.*, 2015; Coria-Avila *et al.*, 2014; Dolen *et al.*, 2013; Loureiro *et al.*, 2016; Vanderschuren *et al.*, 2016) and have been initially identified as neurochemical mediators of the motivational/rewarding properties of drugs of abuse and/or as pain killers. In contrast, neurobiological substrates of social avoidance (social avoidance systems – SAS) have been characterized as main factors of the pain, aggression or stress systems, and include

serotonin, glucocorticoids and neuropeptides such as corticotropin-releasing factor (CRF), arginine vasopressin, substance P or cholecystokinin (Barik *et al.*, 2013; Gobrogge *et al.*, 2016; Katsouni *et al.*, 2009; Katsouni *et al.*, 2013; Takahashi *et al.*, 2012). Prosocial and antisocial neuromodulators thus compete to drive adaptive social behaviour in individuals. In the following section, we will focus on the role of opioids and, more specifically, of the μ opioid receptor (μ OR), in this subtle balance.

The μ opioid receptor is a critical neurobiological substrate of social behaviour

The opioid receptors belong to the large family of G-protein coupled receptors (GPCR) and include three members: μ , δ and κ opioid receptors respectively μ OR, δ OR and κ OR, whose preferential endogenous ligands are the opioid peptides enkephalins, endorphins and dynorphins, respectively. The opioid system is a well-known key modulator of pain, and exogenous ligands of opioid receptors, opiates, have been used for thousands of years as pain killers. Medicinal use of opiates, however, has also led to the discovery of their addictive properties, shedding light on a second major physiological role of opioids: modulating reward processes. The identification of opioid peptides, their receptors and respective genes has since allowed a better understanding of their mechanism of action, regarding the control of pain and reward (Le Merrer *et al.*, 2009) as well as multiple other roles in stress response, respiration, food intake, gastrointestinal transit, endocrine and immune processes (Plein *et al.*, 2017; Sobczak *et al.*, 2014; Yamanaka *et al.*, 2013).

In 1978, Panksepp and colleagues formulated their “Brain Opioid Theory of Social Attachment” (BOTSA), in which social and affiliative behaviours are proposed to tightly depend on the level of endogenous opioid peptides, based notably on striking similarities between social attachment and drug addiction (Panksepp *et al.*, 1978). BOTSA hypothesizes that social deprivation induces social distress and contact seeking due to insufficient opioid tone (opioid withdrawal). Social contact would relieve this negative affect by triggering opioid (endorphin) release. Since then, experimental evidence has accumulated showing that μ OR are primarily involved in prosocial effects of opioids, which are not exclusively observed under social distress

conditions (social deprivation or defeat) but also in more neutral or even positive social situations (social comfort). We review these data in the next subsections.

Role of μ OR under social distress conditions

With regards to the role of μ OR under social distress conditions (summary and references in Table 1 and Figure 1), the first evidence came from the observation that μ OR agonists in infant rodents or monkeys can reduce the severe distress and ultrasound vocalisations (USV) triggered by separation from the mother. Similarly, in young adults, μ OR agonists restore social interaction deficits and decrease defensive/submissive behaviour and USVs in isolated and defeated animals. Although social play is a highly rewarding and conserved behaviour in young social mammals (Vanderschuren *et al.*, 2016), the common use is to isolate animals prior to its study, to increase social seeking (Table 1). In such mild negative social conditions, μ OR agonists delivered systemically increase social play and motivation to play, and reverse social dominance in juvenile rodents or monkeys. Furthermore, direct injection of μ OR agonists in the NAc is sufficient to enhance social play, in accordance with the hedonic properties of μ OR activation in this region. Besides, exposure to negative social contexts modifies brain μ OR expression (Figure 1), notably in the NAc and VTA (Chajale *et al.*, 2013; Nikulina *et al.*, 2005; Rodriguez-Arias *et al.*, 2016; Vanderschuren *et al.*, 1995c). In contrast with agonists, opioid antagonists exacerbate social distress and USV, and increase the incidence of defensive postures. Together, therefore, pharmacological data in animals suggest that μ OR activation can relieve distress in animals experiencing aversive social situations whereas μ OR blockade exacerbates such distress. In humans, imaging studies have revealed the activation of μ OR under conditions of social rejection (notably in the NAc, amygdala and PAG) that correlated with lower levels of sadness and feeling of rejection, suggesting that μ OR in these regions plays a protective or adaptive role in social pain (Hsu *et al.*, 2015; Hsu *et al.*, 2013) (Figure 1). Whereas 6 other rare polymorphisms exist, the A118G polymorphism of the *OPRM1* gene (coding for the μ opioid receptor), removing a potential extracellular N-glycosylation site, is commonly found in European and Asian populations (15-60%) and considered as a gain-of-function *in vitro* and *in vivo* (Kroslak *et al.*, 2007; Sia *et al.*, 2008). A118G polymorphism carriers exhibit increased sensitivity to dramatic social rejection, leading to higher depression scores in adults (Carver *et al.*, 2016; Hsu *et*

al., 2013; Slavich *et al.*, 2014; Way *et al.*, 2009), more negative personality and impaired emotional, behavioural and social skills in children (Bertoletti *et al.*, 2012; Carver *et al.*, 2016). These last data suggest that μ OR hyperactivity can be detrimental to coping with highly negative social experiences.

Role of μ OR under neutral/positive social conditions

The role of μ OR activation has also been extensively studied under conditions of social comfort (Table 1). In such context, low to moderate μ OR activation facilitates social behaviour. In rats, μ OR agonists increase socio-sexual and sexual behaviours, bias spatial exploration in an unfamiliar environment towards social play and enhance long-term social memory. In contrast, blockade of μ OR activity inhibits various social behaviours when administered under neutral social context in animals, including social interaction, social play, affiliative and sexual or socio-sexual behaviours. μ OR in the NAc play a critical role in socio-sexual behaviour, as its expression in this structure is enriched in monogamous species (Inoue *et al.*, 2013; Ragen *et al.*, 2015a) and intra-NAc administration of antagonists abolishes partner preference formation (Table 1 and Figure 1). Remarkably, administering an opioid antagonist during the first 4 post-natal days in mice leads to social impairment and anhedonia in adult age. In humans, psychopharmacological studies have revealed that a low dose of μ OR agonist increases female face attractiveness and avoidance of the least attractive female faces in men. Partial agonists improve memory for happy faces, increase pleasantness ratings of neutral or social images and decrease perception of social rejection (Table 1). Moreover, positive social stimuli such as social acceptance or pleasant social touch modify μ OR availability in common structures (Hsu *et al.*, 2013; Nummenmaa *et al.*, 2016) (Figure 1). In contrast with agonists, opioid antagonists decrease facial emotional responses to happy faces, decrease female face attractiveness and reduce feelings of social connection in young adults. In humans, adult carriers of the A118G *OPRM1* polymorphism show less avoidance of affectionate relationships and increased capacity to experience social reward (Troisi *et al.*, 2011) whereas child carriers display improved relationships, better resilience to aversive parental care and enhanced responses to facial expression of social and emotional stimuli (Bertoletti *et al.*, 2012; Copeland *et al.*, 2011; Troisi *et al.*, 2011). Consistent with this, A118G *OPRM1* knock-in mice exhibit increased social interaction, dominance and protection from social defeat

(Briand *et al.*, 2015; Mague *et al.*, 2009). Similarly, C77G polymorphism in macaques, equivalent to the human A118G polymorphism, results in higher affiliative behaviour in mothers and infants (Barr *et al.*, 2008; Higham *et al.*, 2011). All these data thus converge to draw a prosocial picture for μ OR under neutral/positive social conditions.

The particular case of excessive and/or prolonged opioid stimulation

Surprisingly, however, several studies have reported that μ OR agonists administered either acutely at a moderate to high dose or chronically at a low dose inhibit various social behaviours such as socio-sexual behaviours, maternal behaviour and duration of direct social exploration independently from the social context (Table 1). Interestingly, in the clinics, former opiate addicts under opioid maintenance (chronic low dose) display social interaction/cognition deficits, report feeling of being unrelated and behave in an autistic way (Johnson *et al.*, 2014; McDonald *et al.*, 2013). In other studies, high doses of a μ OR agonist, given acutely or chronically, reduce socio-sexual behaviour, social play and impair long-term social memory in animals. Furthermore, exposure to high doses of opiates affects social behaviour in the long term, as mice exposed to escalating doses of morphine or heroin display severe social interaction deficit up to 7 weeks after cessation of treatment (Table 1). Of note, brain transcription of opioid peptides is reduced after 4 weeks in abstinent animals (Becker *et al.*, in press) suggesting that excessive opioid stimulation results in long lasting adaptive peptide down-regulation. Accordingly, opiate abstinent patients without substitutive therapy show low levels of circulating β -endorphin (Shi *et al.*, 2009) and display reduced prefrontal response to social stimuli, pointing to social behaviour deficits (Huhn *et al.*, 2016). Together, these data indicate that, when excessive and/or prolonged, μ OR activation can exert a deleterious influence on social behaviour.

The μ OR Balance Model

In an attempt to solve the paradox of divergent effects of μ OR stimulation on social behaviours depending on species (rodents versus primates/humans), a “State-dependent μ -Opioid Modulation of Social Motivation” (SOMSOM) model was recently proposed. This model postulates that the effects of μ OR agonists and antagonists depend on the social motivational state of the animals when assessing their behaviour, namely whether they are trying to reduce distress or seeking a

pleasurable experience (Loseth *et al.*, 2014). In this model, the initial social context is the crucial determinant of future effects of opioid manipulation on sociability. However, although this model successfully predicts the consequences of μ OR stimulation and inhibition under social distress or comfort conditions, it fails to account for negative consequences of intense and/or long-lasting μ OR stimulation. Extending the SOMSOM model, we propose a μ OR Balance Model (Figure 2), in which the key determinant to predict the consequences of opioid/ μ OR manipulation on social behaviour is the initial μ OR activity. In this model, both excessive and deficient μ OR activity negatively impact social behaviour through a classical inverted-U relationship (Johnson *et al.*, 2014). In a narrow window of optimal functioning, μ OR activity could be balanced with social avoidance systems (SAS) to allow adaptive social behaviour. In contrast, blunted μ OR activity, due to social distress or pharmacological antagonism, leads to reduced social reward/motivation and leaves the field clear for social avoidance systems to elicit social withdrawal. Similarly, excessive μ OR stimulation due to intense/prolonged exposure to opioids saturates the reward system and produces social indifference. In this framework, blocking μ OR activity in the case of excessive tone, or stimulating μ OR when the tone is too low, can restore normal, adaptive, social behaviour. The μ OR Balance Model thus reconciles experimental discrepancies regarding the social consequences of μ OR stimulation depending on species and social context.

μ OR manipulation in different social contexts might face some technical issues of other unspecific functions of the μ OR (locomotion, sedation) impacting on social behaviour. However, our conclusions are drawn on studies involving different dose of μ OR ligands and studying different kind of social behaviours but also non-social behaviours excluding technical issues regarding other μ OR functions and their impacts on social behaviours.

Genetic manipulations of the μ opioid receptor and autistic-like syndrome in mice

Genetic knockout of μ OR (*Oprm1*^{-/-}) produces severe alterations of social behaviour in mice. Indeed, mouse pups lacking μ OR vocalise less when separated from their mother (Cinque *et al.*, 2012; Moles *et al.*, 2004), juvenile *Oprm1*^{-/-} mice exhibit

reduced interest in social partners (Cinque *et al.*, 2012), young adult *Oprm1*^{-/-} males respond less to female vocalisations (Gigliucci *et al.*, 2014; Wöhr *et al.*, 2011) and *Oprm1*^{-/-} male and female animals display reduced social interaction and preference (Becker *et al.*, 2014). However, when exposed to chronic social defeat, μ OR knockout animals show less aversion to the social context (Komatsu *et al.*, 2011). These data fit with the μ OR Balance Model (insufficient μ OR tone) and further demonstrate that μ OR is essential for establishing appropriate social behaviour.

Interestingly, *Oprm1*^{-/-} mice were recently proposed as a monogenic mouse model of Autism Spectrum Disorders (ASD) (Becker *et al.*, 2014; Oddi *et al.*, 2013). ASD are complex neurodevelopmental diseases whose diagnosis is based on the detection of two types of behavioural symptoms (core symptoms): impaired social reciprocity and communication together with restricted, repetitive patterns of behaviour, interests or activities (Diagnostic and Statistical Manual of Mental Disorders: DSM-5). Comorbid symptoms, variable in their occurrence and intensity, are frequently associated to ASD, and encompass anxiety disorders, cognitive and motor deficits, aggressive behaviour, epileptic episodes, sleep disturbances, increased sensitivity to pain and altered gastro-intestinal transit (Chen *et al.*, 2016; Johnson *et al.*, 2007; Mazurek *et al.*, 2013; Robinson, 2012; Veenstra-VanderWeele *et al.*, 2012; White *et al.*, 2012; Whyatt *et al.*, 2013). Intriguingly, in addition to deficits in social behaviour, *Oprm1*^{-/-} mice show stereotyped and perseverative behaviours, necessary to fulfil ASD criteria, as well as multiple comorbid symptoms of ASD, namely increased aggressiveness, exacerbated anxiety and motor clumsiness (Becker *et al.*, 2014), increased susceptibility to seizures (Becker *et al.*, 2014; Grecksch *et al.*, 2004; Jang *et al.*, 2001), impaired spatial learning (Jamot *et al.*, 2003), lowered nociceptive thresholds (Gaveriaux-Ruff *et al.*, 2002) and reduced gastrointestinal motility (Roy *et al.*, 1998). μ OR null mice thus recapitulate the broadest autistic syndrome ever reported in preclinical research, proving unique face validity. Moreover, *Oprm1*^{-/-} mice display anatomical, neurochemical and genetic landmarks of the disease, such as modified neuronal activation in anxiety- and reward-associated brain structures, reduced striatal connectivity, altered synaptic morphology and monoamine levels in the striatum and modified expression of several candidate genes of autism, providing construct validity to the model (Becker *et al.*, 2014; Mechling *et al.*, 2016). Finally, as regards predictive validity, risperidone and oxytocin, compounds that demonstrated

efficiency in relieving autistic features in patients, also alleviated such symptoms in μ OR null mice (Becker *et al.*, 2014; Gigliucci *et al.*, 2014). Together, these results establish the *Oprm1*^{-/-} mouse line as a comprehensive model of ASD and demonstrate that genetic invalidation of μ OR is sufficient to trigger an autistic syndrome in these rodents.

Preclinical studies exploring *MECP2*-related genetic diseases further support the hypothesis of a tight link between ASD and μ OR. The *MECP2* gene codes for methyl-CpG binding protein 2, which binds DNA at methylated sites to either repress or activate transcription (Chahrour *et al.*, 2008). Genetic invalidation of *Mecp2* in mice is a model for Rett syndrome, which includes autistic features; conversely, *Mecp2* duplication mimics the *MECP2* duplication syndrome, which also encompasses autistic symptoms (Lombardi *et al.*, 2015). Remarkably, μ OR expression is decreased in the striatum of *Mecp2* null mice (Kao *et al.*, 2015), consistent with a critical role of μ OR in the striatum in supporting social behaviour. In mice bearing multiple copies of *Mecp2*, however, μ OR expression is instead excessive, and breeding these animals with heterozygous *Oprm1*^{+/-} mice corrects both high μ OR expression and deficient social interaction (Samaco *et al.*, 2012). These data fit the μ OR Balance Model, with both deficient and excessive signalling having deleterious consequences (Figure 2). Most importantly, they further establish a connection between μ OR and ASD, suggesting that defective μ OR function could account for decreased social reward/motivation in these disorders.

Evidences for blunted reward processes in Autism Spectrum Disorders

In search for the neurobiological underpinnings of disrupted social interactions in ASD, autism research had initially focused on cognitive impairments and involved theory-of-mind deficits, or altered ability to infer other's mental states. Recently, however, motivational aspects of social skills have received more attention, and a social motivation theory has emerged (Chevallier *et al.*, 2012; Dawson *et al.*, 2007). In this framework, disrupted social interest in ASD patients would result from early deficits in social motivation, including interest in attending social stimuli, as well as enjoying and prolonging reciprocal social interactions. Such interactions being

intrinsically rewarding (Fehr *et al.*, 2007; Neuhaus *et al.*, 2010; Trezza *et al.*, 2010), the social motivation theory thus suggests that reward and/or social reward processes are altered in patients with ASD.

Consistent with this hypothesis, numerous psychological studies have shown diminished sensitivity to the positive reward value of social stimuli in subjects with ASD (Chevallier *et al.*, 2012; Dubey *et al.*, 2015; Kim *et al.*, 2015; Lin *et al.*, 2012; Sasson *et al.*, 2012; Scott-Van Zeeland *et al.*, 2010). Accordingly, electrophysiological (Gonzalez-Gadea *et al.*, 2016; Stavropoulos *et al.*, 2014) and pupillary (Sepeta *et al.*, 2012) responses as well as neural activation in brain areas involved in reward anticipation and/or processing (notably PFC and NAc) (Assaf *et al.*, 2013; Choi *et al.*, 2015; Kohls *et al.*, 2012; Kohls *et al.*, 2014; Leung *et al.*, 2015; Richey *et al.*, 2014; Scott-Van Zeeland *et al.*, 2010) are diminished in ASD patients presented with social stimuli (Figure 3). Of note, subjects with ASD also display hypo-activated NAc and CPu while anticipating negative social reinforcement (Damiano *et al.*, 2015) and diminished activity in the social brain circuitry (including PFC and amygdala) in response to social touch (Kaiser *et al.*, 2016). As regards the amygdala and insular cortex, also involved in reward processing, studies have reported either hypo-activation (Kaiser *et al.*, 2016; Kohls *et al.*, 2012; Leung *et al.*, 2015) or hyper-activation (Dichter *et al.*, 2012b) in response to social stimuli in ASD subjects, maybe due to different experimental settings. Together, these data strongly support the hypothesis of deficient social reward in patients with ASD, as a likely consequence of abnormal activation of the brain reward circuit in social contexts.

Clinical data relative to other (non-social) rewarding stimuli appear less consistent. Concerning primary rewards, individuals with ASD were reported to display intact hedonic responses to sweet taste (Damiano *et al.*, 2014) and stronger activation in brain reward regions (NAc, orbitofrontal cortex, amygdala, insula) in response to food cues (Cascio *et al.*, 2012a) pointing to increased food reward in these patients. In line with this, children with ASD were shown as less able to delay gratification when tested for a food reward (Faja *et al.*, 2015). In contrast, ASD subjects exhibited diminished brain activation for pleasant (and neutral) tactile texture stimuli (Cascio *et al.*, 2012b) and young children with ASD were impaired in learning an abstract rule from a discrete physical reward (small toy) (Jones *et al.*, 2013). Consistent with this, when presented with an object incentive, adults with ASD showed decreased activation in the dorsal ACC but increased activation in the paracingulate gyrus and

other frontal regions (Dichter *et al.*, 2012a). These data suggest that reward processing for these stimuli is altered in ASD patients. Regarding secondary rewards, some studies have reported unchanged anticipation and processing of monetary reward (Dvash *et al.*, 2014) and no modification of neural responses during monetary choices (Gonzalez-Gadea *et al.*, 2016) in patients with ASD. In other reports, these patients were shown to be less sensitive to monetary incentive (Kohls *et al.*, 2014; Lin *et al.*, 2012; Scott-Van Zeeland *et al.*, 2010), notably when making effort-based decisions (Damiano *et al.*, 2012), and more sensitive to monetary loss (South *et al.*, 2014). Accordingly, imaging studies have evidenced hypo-activation in the mesocorticolimbic circuitry (NAc, CPu and midbrain) during monetary anticipation or outcome in ASD patients (Dichter *et al.*, 2012a; Dichter *et al.*, 2012b; Kohls *et al.*, 2012; Richey *et al.*, 2014) (Figure 3). Moreover, children with ASD were found to display reduced activation of the right CPu when anticipating monetary loss (Damiano *et al.*, 2015). Finally, when reward stimulus was a positive feedback (“Correct!” printed on screen) versus negative feedback (“incorrect!”), young adults with ASD displayed impaired ability to develop an effective reward-based working memory (Solomon *et al.*, 2015). These data converge towards altered processing of secondary reward in ASD patients. However, ASD subjects can attribute higher positive ratings for non-social stimuli whenever these stimuli match their restricted interests (trains and electronics) (Sasson *et al.*, 2012; Watson *et al.*, 2015). Non-social reward processes thus appear unevenly affected by ASD, with food reward and restricted interests showing increased motivational value whereas other stimuli show blunted motivational properties.

Methodological issues should be mentioned, though, that may limit previous conclusions. Indeed, a major difficulty in clinical ASD research lies in recruiting patients. Notably, sample size in a majority of studies is small and the age of participants is highly heterogeneous (young children, adolescents, adults) as well as patient’s use of psychotropic medications or involvement in behavioural therapy programs, which has significant consequences on reward processing (Pankert *et al.*, 2014). Most importantly, clinical studies suffer from a major IQ bias: they focus on a population of subjects with IQ in a normal range, namely higher functioning ASD patients. This bias is essentially due to technical issues, as most psychological tasks and imaging settings in previous studies are too demanding and restrictive for lower functioning subjects. The possibility that the latter patients present more severe

reward deficits has thus never been explored. Of importance though, conditioned learning mechanisms are set very early in the course of human infant development (Rovee-Collier, 1999) and depend tightly, as regards appetitive aspects, on the integrity of the reward system (Dayan *et al.*, 2002; O'Doherty *et al.*, 2016). Major deficits in reward processing may thus result in cognitive impairment, such as observed in low functioning ASD patients, highlighting the interest of evaluating reward in this population.

In conclusion, clinical data have evidenced deficient reward processing in patients with ASD, for social and secondary (monetary) stimuli. The neurobiological substrates of this deficit remain to be identified, and one plausible candidate is a dysfunction of the opioid system.

The opioid hypothesis in autism

As a straightforward consequence of BOTSA (Panksepp *et al.*, 1978), Panksepp proposed for the first time in 1979 that autism would be an emotional disorder caused by excessive brain opioid activity and, therefore, that opioid antagonists should be beneficial to treat this pathology (Panksepp, 1979). The last hypothesis was later tested by administering naltrexone to ASD patients. Several clinical trials evidenced beneficial effects of naltrexone in reducing hyperactivity and irritability, but failed to detect an improvement in core autistic symptoms (reviewed in (Roy *et al.*, 2015)), except maybe in a subgroup of patients with high blood levels of β -endorphins (Bouvard *et al.*, 1995; Leboyer *et al.*, 1992). Consistent with the excessive opioid hypothesis, several studies have reported increased (but also decreased) levels of opioid peptides in plasma, urinary and cerebrospinal fluid samples from patients with ASD (Table 2). Reichelt and colleagues proposed a dietary origin for urine peptides (Reichelt *et al.*, 1991) and therefore recommended a gluten- and casein-free diet to relieve ASD (Knivsberg *et al.*, 1999). Technical issues were raised, however, regarding the dosage of urinary opioid peptides that challenged Reichelt's hypothesis and led to a still active scientific controversy. Further questioning the excessive opioid theory, reviews and meta-analyses have examined clinical evidence for the efficacy of dietary intervention in autism and concluded for a lack of consistent effects (Dosman *et al.*, 2013; Lange *et al.*, 2015; Mari-Bauset *et al.*, 2014). In sum, technical concerns and disappointing clinical

results have argued against the excessive opioid theory of autism and, more generally, dissuaded the scientific community from considering dysfunction in the opioid system as a plausible neurobiological substrate for autism.

The hypothesis of excessive opioid activity in autism fits into the excessive opioid tone window of our μ OR Balance Model (Figure 2). However, this model also predicts that ASD could result from insufficient opioid tone. Interestingly, in the clinics, evidence exists that support both propositions. Dosage studies have examined levels of opioid peptides in various biological samples from patients with autism. As regards plasma samples, most studies have detected an increase in circulating β -endorphin in subjects with ASD (or their mothers) or Rett syndrome (Table 2). Whether such increase would reflect an excessive opioid tone in these patients, or instead a compensation for defective opioid signalling, as suggested by abnormal β -endorphin immunoreactivity (Leboyer *et al.*, 1994) or decreased μ OR expression in a mouse model of Rett syndrome (Kao *et al.*, 2015), has not been explored yet. Of note however, low doses of naltrexone, known to stimulate μ OR expression (Brown *et al.*, 2009), significantly relieved autistic symptoms in several ASD patients (Bouvard *et al.*, 1995; Leboyer *et al.*, 1992). Regarding cerebrospinal fluid and urine samples, results from β -endorphin or, more generally, opioid peptide dosage appear inconsistent, maybe due to methodological issues. Urinary exogenous (presumably dietary) opioid peptides have been detected in several studies, though (Table 2). Together, these data argue for a link between opioid tone and ASD, in either direction (excessive or deficient tone). Genetic studies further support the existence of such connection. We browsed the SFARIgene^{2.0} database (<https://gene.sfari.org/autdb/Welcome.do>) in search for mutations affecting opioid genes in ASD patients. We failed to find mutations in genes coding for the precursors of endorphins (*POMC*) or dynorphins (*PDYN*) and for δ OR or κ OR (*OPRD1*, *OPRK1*). We found one patient with a genetic deletion including *PENK*, coding for proenkephalin (Kaminsky *et al.*, 2011). Strikingly, however, we found 10 patients with mutations affecting the *OPRM1* gene (Figure 4). For comparison, mutations in *CNR1*, coding for the CB₁ cannabinoid receptor, another candidate gene for ASD involved in reward processing (Chakrabarti *et al.*, 2006), are not reported in the SFARIgene^{2.0} database. In addition, *OPRM1* mutations are all associated with intellectual deficiency, suggesting that compromised μ OR function in

humans can lead to IQ impairment. Genetic data thus demonstrate that genetic μ OR ablation is sufficient to produce ASD in humans, as it is in mice (Becker *et al.*, 2014). Direct genetic mutation, though, is not the only mean to impair the expression and function of a GPCR, as illustrated by the effects of *Mecp2* genetic manipulation on μ OR expression in mice. Whether mutations in other candidate genes for autism identified from sequencing studies could impact μ OR signalling thus needs to be carefully explored.

Conclusion

Recent advances in brain imaging and sustained efforts towards identifying the genetic and neurobiological substrates of social impairment in ASD, including characterisation of mouse models, have revived the exciting field of opioids and social behaviour. These studies have provided the demonstration that, among factors of the opioid system, μ OR is the key substrate for the control of social behaviour. In an attempt to better capture the role of μ OR in this control, we propose here a new model, the μ OR Balance Model, in which both deficient and excessive μ OR signalling results in social behaviour impairments. How this model could apply to other opioid-dependent functions would deserve further investigation. Importantly, altered μ OR function has been clearly proved to be *sufficient* to hamper social abilities, making it a plausible contributor to ASD. Dedicated studies are now required to explore the *necessity* of μ OR dysfunction for social impairment in such pathologies. Remarkably, pharmacological treatments can relieve autistic-like symptoms in μ OR null mice (Becker *et al.*, 2014; Gigliucci *et al.*, 2014), suggesting that whether μ OR dysfunction would be a core mechanism in ASD, promising therapeutic strategies exist that can overcome such dysfunction.

Nomenclature of Targets and Ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan *et al.*, 2016), and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander *et al.*, 2015).

Conflict of interest statement

The authors declare no conflict of interest.

Acknowledgments

This work was supported by the Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Recherche Agronomique (INRA) and Université François Rabelais de Tours. We thank Région Centre-Val de Loire (ARD2020 Biomédicaments – GPCRAb) for support in this project. L.P. Pellissier acknowledges postdoctoral support from the Marie-Curie/AgreenSkills Program.

References

Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, *et al.* (2015). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. *British journal of pharmacology* **172**(24): 5744-5869.

Assaf M, Hyatt CJ, Wong CG, Johnson MR, Schultz RT, Hendler T, *et al.* (2013). Mentalizing and motivation neural function during social interactions in autism spectrum disorders. *Neuroimage Clin* **3**: 321-331.

Baribeau DA, Anagnostou E (2015). Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. *Front Neurosci* **9**: 335.

Barik J, Marti F, Morel C, Fernandez SP, Lanteri C, Godeheu G, *et al.* (2013). Chronic stress triggers social aversion via glucocorticoid receptor in dopaminergic neurons. *Science* **339**(6117): 332-335.

Barr CS, Schwandt ML, Lindell SG, Higley JD, Maestripieri D, Goldman D, *et al.* (2008). Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. *Proc Natl Acad Sci U S A* **105**(13): 5277-5281.

Battaglia A, Doccini V, Bernardini L, Novelli A, Loddo S, Capalbo A, *et al.* (2013). Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features. *Eur J Paediatr Neurol* **17**(6): 589-599.

Becker JA, Clesse D, Spiegelhalter C, Schwab Y, Le Merrer J, Kieffer BL (2014). Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity. *Neuropsychopharmacology* **39**(9): 2049-2060.

Becker JA, Kieffer BL, Le Merrer J (in press). Differential behavioral and molecular alterations upon protracted abstinence from cocaine versus morphine, nicotine, THC and alcohol. *Addict Biol*.

Benton D, Smoothy R, Brain PF (1985). Comparisons of the influence of morphine sulphate, morphine-3-glucuronide and tifluadom on social encounters in mice. *Physiol Behav* **35**(5): 689-693.

Bershad AK, Seiden JA, de Wit H (2016). Effects of buprenorphine on responses to social stimuli in healthy adults. *Psychoneuroendocrinology* **63**: 43-49.

Bertoletti E, Zanoni A, Giorda R, Battaglia M (2012). Influence of the OPRM1 gene polymorphism upon children's degree of withdrawal and brain activation in response to facial expressions. *Dev Cogn Neurosci* **2**(1): 103-109.

Bianchi E, Menicacci C, Ghelardini C (2013). Dual effect of morphine in long-term social memory in rat. *British journal of pharmacology* **168**(8): 1786-1793.

Bouvard MP, Leboyer M, Launay JM, Recasens C, Plumet MH, Waller-Perotte D, *et al.* (1995). Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. *Psychiatry Res* **58**(3): 191-201.

Brambilla F, Guareschi-Cazzullo A, Tacchini C, Musetti C, Panerai AE, Sacerdote P (1997). Beta-endorphin and cholecystokinin 8 concentrations in peripheral blood mononuclear cells of autistic children. *Neuropsychobiology* **35**(1): 1-4.

Briand LA, Hilario M, Dow HC, Brodtkin ES, Blendy JA, Berton O (2015). Mouse model of OPRM1 (A118G) polymorphism increases sociability and dominance and confers resilience to social defeat. *J Neurosci* **35**(8): 3582-3590.

Brown N, Panksepp J (2009). Low-dose naltrexone for disease prevention and quality of life. *Med Hypotheses* **72**(3): 333-337.

Burkett JP, Spiegel LL, Inoue K, Murphy AZ, Young LJ (2011). Activation of mu-opioid receptors in the dorsal striatum is necessary for adult social attachment in monogamous prairie voles. *Neuropsychopharmacology* **36**(11): 2200-2210.

Cacioppo JT, Hawkley LC, Norman GJ, Berntson GG (2011). Social isolation. *Ann N Y Acad Sci* **1231**: 17-22.

Carden SE, Barr GA, Hofer MA (1991). Differential effects of specific opioid receptor agonists on rat pup isolation calls. *Brain Res Dev Brain Res* **62**(1): 17-22.

Carver CS, Johnson SL, Kim Y (2016). Mu opioid receptor polymorphism, early social adversity, and social traits. *Soc Neurosci* **11**(5): 515-524.

Cascio CJ, Foss-Feig JH, Heacock JL, Newsom CR, Cowan RL, Benningfield MM, *et al.* (2012a). Response of neural reward regions to food cues in autism spectrum disorders. *J Neurodev Disord* **4**(1): 9.

Cascio CJ, Moana-Filho EJ, Guest S, Nebel MB, Weisner J, Baranek GT, *et al.* (2012b). Perceptual and neural response to affective tactile texture stimulation in adults with autism spectrum disorders. *Autism Res* **5**(4): 231-244.

Cass H, Gringras P, March J, McKendrick I, O'Hare AE, Owen L, *et al.* (2008). Absence of urinary opioid peptides in children with autism. *Arch Dis Child* **93**(9): 745-750.

Cazzullo AG, Musetti MC, Musetti L, Bajo S, Sacerdote P, Panerai A (1999). Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. *Eur Neuropsychopharmacol* **9**(4): 361-366.

Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, *et al.* (2008). MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science* **320**(5880): 1224-1229.

Chajale NN, Curtis AL, Wood SK, Zhang XY, Bhatnagar S, Reyes BA, *et al.* (2013). Social stress engages opioid regulation of locus coeruleus norepinephrine neurons and induces a state of cellular and physical opiate dependence. *Neuropsychopharmacology* **38**(10): 1833-1843.

Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S (2006). Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. *Eur J Neurosci* **23**(7): 1944-1948.

Chelnokova O, Laeng B, Eikemo M, Riegels J, Loseth G, Maurud H, *et al.* (2014). Rewards of beauty: the opioid system mediates social motivation in humans. *Mol Psychiatry* **19**(7): 746-747.

Chen C, Hung AY, Fan YT, Tan S, Hong H, Cheng Y (2016). Linkage between pain sensitivity and empathic response in adolescents with autism spectrum conditions and conduct disorder symptoms. *Autism Res*.

Chen Z, Williams KD, Fitness J, Newton NC (2008). When hurt will not heal: exploring the capacity to relive social and physical pain. *Psychological science* **19**(8): 789-795.

Chevallier C, Grezes J, Molesworth C, Berthoz S, Happe F (2012). Brief report: Selective social anhedonia in high functioning autism. *J Autism Dev Disord* **42**(7): 1504-1509.

Choi US, Kim SY, Sim HJ, Lee SY, Park SY, Jeong JS, *et al.* (2015). Abnormal brain activity in social reward learning in children with autism spectrum disorder: an fMRI study. *Yonsei Med J* **56**(3): 705-711.

Cinque C, Pondiki S, Oddi D, Di Certo MG, Marinelli S, Troisi A, *et al.* (2012). Modeling socially anhedonic syndromes: genetic and pharmacological manipulation of opioid neurotransmission in mice. *Transl Psychiatry* **2**: e155.

Copeland WE, Sun H, Costello EJ, Angold A, Heilig MA, Barr CS (2011). Child mu-opioid receptor gene variant influences parent-child relations. *Neuropsychopharmacology* **36**(6): 1165-1170.

Coria-Avila GA, Manzo J, Garcia LI, Carrillo P, Miquel M, Pfaus JG (2014). Neurobiology of social attachments. *Neurosci Biobehav Rev* **43**: 173-182.

Coudereau JP, Monier C, Bourre JM, Frances H (1997). Effect of isolation on pain threshold and on different effects of morphine. *Prog Neuropsychopharmacol Biol Psychiatry* **21**(6): 997-1018.

Damiano CR, Aloï J, Burrus C, Garbutt JC, Kampov-Polevoy AB, Dichter GS (2014). Intact Hedonic Responses to Sweet Tastes in Autism Spectrum Disorder. *Res Autism Spectr Disord* **8**(3): 230-236.

Damiano CR, Aloï J, Treadway M, Bodfish JW, Dichter GS (2012). Adults with autism spectrum disorders exhibit decreased sensitivity to reward parameters when making effort-based decisions. *J Neurodev Disord* **4**(1): 13.

Damiano CR, Cockrell DC, Dunlap K, Hanna EK, Miller S, Bizzell J, *et al.* (2015). Neural mechanisms of negative reinforcement in children and adolescents with autism spectrum disorders. *J Neurodev Disord* **7**(1): 12.

Dawson G, Bernier R (2007). Development of social brain circuitry in autism. In: Coch D, Dawson, G., & Fischer, K. (ed) (eds). *Human behavior and the developing brain: Atypical development* 2nd ed. edn. New York: Guilford Press. pp 28-55.

Dayan P, Balleine BW (2002). Reward, motivation, and reinforcement learning. *Neuron* **36**(2): 285-298.

Defeudis FV, Defeudis PA, Somoza E (1976). Altered analgesic responses to morphine in differentially housed mice. *Psychopharmacology (Berl)* **49**(1): 117-118.

Dettmer K, Hanna D, Whetstone P, Hansen R, Hammock BD (2007). Autism and urinary exogenous neuropeptides: development of an on-line SPE-HPLC-tandem mass spectrometry method to test the opioid excess theory. *Anal Bioanal Chem* **388**(8): 1643-1651.

Dichter GS, Felder JN, Green SR, Rittenberg AM, Sasson NJ, Bodfish JW (2012a). Reward circuitry function in autism spectrum disorders. *Soc Cogn Affect Neurosci* **7**(2): 160-172.

Dichter GS, Richey JA, Rittenberg AM, Sabatino A, Bodfish JW (2012b). Reward circuitry function in autism during face anticipation and outcomes. *J Autism Dev Disord* **42**(2): 147-160.

Dolen G, Darvishzadeh A, Huang KW, Malenka RC (2013). Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. *Nature* **501**(7466): 179-184.

Dosman C, Adams D, Wudel B, Vogels L, Turner J, Vohra S (2013). Complementary, holistic, and integrative medicine: autism spectrum disorder and gluten- and casein-free diet. *Pediatr Rev* **34**(10): e36-41.

Dubey I, Ropar D, Hamilton AF (2015). Measuring the value of social engagement in adults with and without autism. *Mol Autism* **6**: 35.

Dvash J, Ben-Zeev A, Noga A, Shamay-Tsoory S (2014). The road not taken: social vs. private comparisons in Aspergers syndrome and high functioning autism. *Psychiatry Res* **216**(3): 385-390.

Eisenberger NI (2012). The pain of social disconnection: examining the shared neural underpinnings of physical and social pain. *Nat Rev Neurosci* **13**(6): 421-434.

Eisenberger NI, Moieni M, Inagaki TK, Muscatell KA, Irwin MR (2016). In Sickness and in Health: The Co-Regulation of Inflammation and Social Behavior. *Neuropsychopharmacology*.

Ernst M, Devi L, Silva RR, Gonzalez NM, Small AM, Malone RP, *et al.* (1993). Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children. *Psychopharmacol Bull* **29**(2): 221-227.

Faja S, Dawson G (2015). Reduced delay of gratification and effortful control among young children with autism spectrum disorders. *Autism* **19**(1): 91-101.

Fareri DS, Chang LJ, Delgado MR (2015). Computational substrates of social value in interpersonal collaboration. *J Neurosci* **35**(21): 8170-8180.

Fehr E, Camerer CF (2007). Social neuroeconomics: the neural circuitry of social preferences. *Trends Cogn Sci* **11**(10): 419-427.

Filipovic D, Todorovic N, Bernardi RE, Gass P (2016). Oxidative and nitrosative stress pathways in the brain of socially isolated adult male rats demonstrating depressive- and anxiety-like symptoms. *Brain Struct Funct*.

Gaveriaux-Ruff C, Kieffer BL (2002). Opioid receptor genes inactivated in mice: the highlights. *Neuropeptides* **36**(2-3): 62-71.

Genazzani AR, Zappella M, Nalin A, Hayek Y, Facchinetti F (1989). Reduced cerebrospinal fluid B-endorphin levels in Rett syndrome. *Childs Nerv Syst* **5**(2): 111-113.

Gigliucci V, Leonzino M, Busnelli M, Luchetti A, Palladino VS, D'Amato FR, *et al.* (2014). Region specific up-regulation of oxytocin receptors in the opioid oprm1 (-/-) mouse model of autism. *Front Pediatr* **2**: 91.

Gillberg C, Terenius L, Hagberg B, Witt-Engerstrom I, Eriksson I (1990). CSF beta-endorphins in childhood neuropsychiatric disorders. *Brain Dev* **12**(1): 88-92.

Gillberg C, Terenius L, Lonnerholm G (1985). Endorphin activity in childhood psychosis. Spinal fluid levels in 24 cases. *Arch Gen Psychiatry* **42**(8): 780-783.

Gobrogge KL, Jia X, Liu Y, Wang Z (2016). Neurochemical Mediation of Affiliation and Aggression Associated With Pair-Bonding. *Biol Psychiatry*.

Goeldner C, Lutz PE, Darcq E, Halter T, Clesse D, Ouagazzal AM, *et al.* (2011). Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. *Biol Psychiatry* **69**(3): 236-244.

Gonzalez-Gadea ML, Sigman M, Rattazzi A, Lavin C, Rivera-Rei A, Marino J, *et al.* (2016). Neural markers of social and monetary rewards in children with Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder. *Sci Rep* **6**: 30588.

Gospic K, Gunnarsson T, Fransson P, Ingvar M, Lindfors N, Petrovic P (2008). Emotional perception modulated by an opioid and a cholecystokinin agonist. *Psychopharmacology (Berl)* **197**(2): 295-307.

Grecksch G, Becker A, Schroeder H, Kraus J, Loh H, Hollt V (2004). Accelerated kindling development in mu-opioid receptor deficient mice. *Naunyn-Schmiedeberg's archives of pharmacology* **369**(3): 287-293.

Guard HJ, Newman JD, Roberts RL (2002). Morphine administration selectively facilitates social play in common marmosets. *Dev Psychobiol* **41**(1): 37-49.

Gunaydin LA, Grosenick L, Finkelstein JC, Kauvar IV, Fenno LE, Adhikari A, *et al.* (2014). Natural neural projection dynamics underlying social behavior. *Cell* **157**(7): 1535-1551.

Halgren C, Kjaergaard S, Bak M, Hansen C, El-Schich Z, Anderson CM, *et al.* (2012). Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of ARID1B. *Clin Genet* **82**(3): 248-255.

Higham JP, Barr CS, Hoffman CL, Mandalaywala TM, Parker KJ, Maestripieri D (2011). Mu-opioid receptor (OPRM1) variation, oxytocin levels and maternal attachment in free-ranging rhesus macaques *Macaca mulatta*. *Behav Neurosci* **125**(2): 131-136.

Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, *et al.* (2015). It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. *Mol Psychiatry* **20**(2): 193-200.

Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Wang H, *et al.* (2013). Response of the mu-opioid system to social rejection and acceptance. *Mol Psychiatry*.

Huhn AS, Meyer RE, Harris JD, Ayaz H, Deneke E, Stankoski DM, *et al.* (2016). Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. *Brain Res Bull* **123**: 102-109.

Inagaki TK, Muscatell KA, Moieni M, Dutcher JM, Jevtic I, Irwin MR, *et al.* (2016a). Yearning for connection? Loneliness is associated with increased ventral striatum activity to close others. *Soc Cogn Affect Neurosci* **11**(7): 1096-1101.

Inagaki TK, Ray LA, Irwin MR, Way BM, Eisenberger NI (2016b). Opioids and social bonding: naltrexone reduces feelings of social connection. *Soc Cogn Affect Neurosci* **11**(5): 728-735.

Inoue K, Burkett JP, Young LJ (2013). Neuroanatomical distribution of mu-opioid receptor mRNA and binding in monogamous prairie voles (*Microtus ochrogaster*) and non-monogamous meadow voles (*Microtus pennsylvanicus*). *Neuroscience* **244**: 122-133.

Jamot L, Matthes HW, Simonin F, Kieffer BL, Roder JC (2003). Differential involvement of the mu and kappa opioid receptors in spatial learning. *Genes Brain Behav* **2**(2): 80-92.

Jang CG, Lee SY, Loh HH, Ho IK (2001). Lack of mu-opioid receptor leads to an increase in the NMDA receptor subunit mRNA expression and NMDA-induced convulsion. *Brain research. Molecular brain research* **94**(1-2): 105-111.

Johnson B, Ulberg S, Shivale S, Donaldson J, Milczarski B, Faraone SV (2014). Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system. *Discov Med* **18**(99): 209-220.

Johnson CP, Myers SM (2007). Identification and evaluation of children with autism spectrum disorders. *Pediatrics* **120**(5): 1183-1215.

Jones EJ, Webb SJ, Estes A, Dawson G (2013). Rule learning in autism: the role of reward type and social context. *Dev Neuropsychol* **38**(1): 58-77.

Kaiser MD, Yang DY, Voos AC, Bennett RH, Gordon I, Pretzsch C, *et al.* (2016). Brain Mechanisms for Processing Affective (and Nonaffective) Touch Are Atypical in Autism. *Cereb Cortex* **26**(6): 2705-2714.

Kalin NH, Shelton SE, Barksdale CM (1988). Opiate modulation of separation-induced distress in non-human primates. *Brain Res* **440**(2): 285-292.

Kalin NH, Shelton SE, Lynn DE (1995). Opiate systems in mother and infant primates coordinate intimate contact during reunion. *Psychoneuroendocrinology* **20**(7): 735-742.

Kaminsky EB, Kaul V, Paschall J, Church DM, Bunke B, Kunig D, *et al.* (2011). An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. *Genet Med* **13**(9): 777-784.

Kao FC, Su SH, Carlson GC, Liao W (2015). MeCP2-mediated alterations of striatal features accompany psychomotor deficits in a mouse model of Rett syndrome. *Brain Struct Funct* **220**(1): 419-434.

Katsouni E, Sakkas P, Zarros A, Skandali N, Liapi C (2009). The involvement of substance P in the induction of aggressive behavior. *Peptides* **30**(8): 1586-1591.

Katsouni E, Zarros A, Skandali N, Tsakiris S, Lappas D (2013). The role of cholecystokinin in the induction of aggressive behavior: a focus on the available experimental data (review). *Acta Physiol Hung* **100**(4): 361-377.

Kawamichi H, Sugawara SK, Hamano YH, Makita K, Kochiyama T, Sadato N (2016). Increased frequency of social interaction is associated with enjoyment enhancement and reward system activation. *Sci Rep* **6**: 24561.

Kim K, Rosenthal MZ, Gwaltney M, Jarrold W, Hatt N, McIntyre N, *et al.* (2015). A Virtual Joy-Stick Study of Emotional Responses and Social Motivation in Children with Autism Spectrum Disorder. *J Autism Dev Disord* **45**(12): 3891-3899.

Knivsberg AM, Reichelt KL, Nodland M (1999). Dietary Intervention for a Seven Year Old Girl with Autistic Behaviour. *Nutr Neurosci* **2**(6): 435-439.

Kohls G, Schulte-Ruther M, Nehr Korn B, Muller K, Fink GR, Kamp-Becker I, *et al.* (2012). Reward system dysfunction in autism spectrum disorders. *Soc Cogn Affect Neurosci*.

Kohls G, Thonessen H, Bartley GK, Grossheinrich N, Fink GR, Herpertz-Dahlmann B, *et al.* (2014). Differentiating neural reward responsiveness in autism versus ADHD. *Dev Cogn Neurosci* **10**: 104-116.

Komatsu H, Ohara A, Sasaki K, Abe H, Hattori H, Hall FS, *et al.* (2011). Decreased response to social defeat stress in mu-opioid-receptor knockout mice. *Pharmacol Biochem Behav* **99**(4): 676-682.

Krosiak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ (2007). The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. *J Neurochem* **103**(1): 77-87.

Kross E, Berman MG, Mischel W, Smith EE, Wager TD (2011). Social rejection shares somatosensory representations with physical pain. *Proc Natl Acad Sci U S A* **108**(15): 6270-6275.

Kudryavtseva NN, Gerrits MA, Avgustinovich DF, Tenditnik MV, Van Ree JM (2004). Modulation of anxiety-related behaviors by mu- and kappa-opioid receptor agonists depends on the social status of mice. *Peptides* **25**(8): 1355-1363.

Lange KW, Hauser J, Reissmann A (2015). Gluten-free and casein-free diets in the therapy of autism. *Curr Opin Clin Nutr Metab Care* **18**(6): 572-575.

Le Merrer J, Becker JA, Befort K, Kieffer BL (2009). Reward processing by the opioid system in the brain. *Physiol Rev* **89**(4): 1379-1412.

Leboyer M, Bouvard MP, Launay JM, Tabuteau F, Waller D, Dugas M, *et al.* (1992). Brief report: a double-blind study of naltrexone in infantile autism. *J Autism Dev Disord* **22**(2): 309-319.

Leboyer M, Bouvard MP, Recasens C, Philippe A, Guilloud-Bataille M, Bondoux D, *et al.* (1994). Difference between plasma N- and C-terminally directed beta-endorphin immunoreactivity in infantile autism. *Am J Psychiatry* **151**(12): 1797-1801.

Leboyer M, Philippe A, Bouvard M, Guilloud-Bataille M, Bondoux D, Tabuteau F, *et al.* (1999). Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. *Biol Psychiatry* **45**(2): 158-163.

Leung RC, Pang EW, Cassel D, Brian JA, Smith ML, Taylor MJ (2015). Early neural activation during facial affect processing in adolescents with Autism Spectrum Disorder. *Neuroimage Clin* **7**: 203-212.

Levy A, Choleris E, Leri F (2009). Enhancing effect of heroin on social recognition learning in male Sprague-Dawley rats: modulation by heroin pre-exposure. *Psychopharmacology (Berl)* **204**(3): 413-421.

Lin A, Rangel A, Adolphs R (2012). Impaired learning of social compared to monetary rewards in autism. *Front Neurosci* **6**: 143.

Lombardi LM, Baker SA, Zoghbi HY (2015). MECP2 disorders: from the clinic to mice and back. *J Clin Invest* **125**(8): 2914-2923.

Loseth GE, Ellingsen DM, Leknes S (2014). State-dependent mu-opioid modulation of social motivation. *Front Behav Neurosci* **8**: 430.

Loureiro M, Kramar C, Renard J, Rosen LG, Laviolette SR (2016). Cannabinoid Transmission in the Hippocampus Activates Nucleus Accumbens Neurons and Modulates Reward and Aversion-Related Emotional Salience. *Biol Psychiatry* **80**(3): 216-225.

Lutz PE, Ayranci G, Chu-Sin-Chung P, Matifas A, Koebel P, Filliol D, *et al.* (2014). Distinct mu, delta, and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence. *Neuropsychopharmacology* **39**(11): 2694-2705.

Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA (2009). Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. *Proc Natl Acad Sci U S A* **106**(26): 10847-10852.

Mari-Bauset S, Zazpe I, Mari-Sanchis A, Llopis-Gonzalez A, Morales-Suarez-Varela M (2014). Evidence of the gluten-free and casein-free diet in autism spectrum disorders: a systematic review. *J Child Neurol* **29**(12): 1718-1727.

Matthews GA, Nieh EH, Vander Weele CM, Halbert SA, Pradhan RV, Yosafat AS, *et al.* (2016). Dorsal Raphe Dopamine Neurons Represent the Experience of Social Isolation. *Cell* **164**(4): 617-631.

Mazurek MO, Vasa RA, Kalb LG, Kanne SM, Rosenberg D, Keefer A, *et al.* (2013). Anxiety, sensory over-responsivity, and gastrointestinal problems in children with autism spectrum disorders. *J Abnorm Child Psychol* **41**(1): 165-176.

McDonald S, Darke S, Kaye S, Torok M (2013). Deficits in social perception in opioid maintenance patients, abstinent opioid users and non-opioid users. *Addiction* **108**(3): 566-574.

Mechling AE, Arefin T, Lee HL, Bienert T, Reisert M, Ben Hamida S, *et al.* (2016). Deletion of the mu opioid receptor gene in mice reshapes the reward-aversion connectome. *Proc Natl Acad Sci U S A* **113**(41): 11603-11608.

Meier IM, Bos PA, Hamilton K, Stein DJ, van Honk J, Malcolm-Smith S (2016). Naltrexone increases negatively-valenced facial responses to happy faces in female participants. *Psychoneuroendocrinology* **74**: 65-68.

Miranda-Paiva CM, Nasello AG, Yin AJ, Felicio LF (2001). Morphine pretreatment increases opioid inhibitory effects on maternal behavior. *Brain Res Bull* **55**(4): 501-505.

Miranda-Paiva CM, Ribeiro-Barbosa ER, Canteras NS, Felicio LF (2003). A role for the periaqueductal grey in opioidergic inhibition of maternal behaviour. *Eur J Neurosci* **18**(3): 667-674.

Moles A, Kieffer BL, D'Amato FR (2004). Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. *Science* **304**(5679): 1983-1986.

Nagamitsu S (1993). CSF beta-endorphin levels in pediatric neurologic disorders. *Kurume Med J* **40**(4): 233-241.

Nagamitsu S, Matsuishi T, Kisa T, Komori H, Miyazaki M, Hashimoto T, *et al.* (1997). CSF beta-endorphin levels in patients with infantile autism. *J Autism Dev Disord* **27**(2): 155-163.

Nelson EE, Panksepp J (1998). Brain substrates of infant-mother attachment: contributions of opioids, oxytocin, and norepinephrine. *Neurosci Biobehav Rev* **22**(3): 437-452.

Neuhaus E, Beauchaine TP, Bernier R (2010). Neurobiological correlates of social functioning in autism. *Clinical psychology review* **30**(6): 733-748.

Nikulina EM, Miczek KA, Hammer RP, Jr. (2005). Prolonged effects of repeated social defeat stress on mRNA expression and function of mu-opioid receptors in the ventral tegmental area of rats. *Neuropsychopharmacology* **30**(6): 1096-1103.

Normansell L, Panksepp J (1990). Effects of morphine and naloxone on play-rewarded spatial discrimination in juvenile rats. *Dev Psychobiol* **23**(1): 75-83.

Nummenmaa L, Tuominen L, Dunbar R, Hirvonen J, Manninen S, Arponen E, *et al.* (2016). Social touch modulates endogenous mu-opioid system activity in humans. *Neuroimage* **138**: 242-247.

O'Doherty JP, Cockburn J, Pauli WM (2016). Learning, Reward, and Decision Making. *Annu Rev Psychol.*

Oddi D, Crusio WE, D'Amato FR, Pietropaolo S (2013). Monogenic mouse models of social dysfunction: implications for autism. *Behav Brain Res* **251**: 75-84.

Pankert A, Pankert K, Herpertz-Dahlmann B, Konrad K, Kohls G (2014). Responsivity to familiar versus unfamiliar social reward in children with autism. *J Neural Transm* **121**(9): 1199-1210.

Panksepp J (1979). A neurochemical theory of autism. *Trends in Neurosciences* **2**(0): 174-177.

Panksepp J, Herman B, Conner R, Bishop P, Scott JP (1978). The biology of social attachments: opiates alleviate separation distress. *Biol Psychiatry* **13**(5): 607-618.

Panksepp J, Jalowiec J, DeEsquinazi FG, Bishop P (1985). Opiates and play dominance in juvenile rats. *Behav Neurosci* **99**(3): 441-453.

Papini MR, Fuchs PN, Torres C (2015). Behavioral neuroscience of psychological pain. *Neurosci Biobehav Rev* **48**: 53-69.

Parkes CM (1975). Psycho-social transitions: comparison between reactions to loss of a limb and loss of a spouse. *The British journal of psychiatry : the journal of mental science* **127**: 204-210.

Parra-Gamez L, Garcia-Hidalgo A, Paredes RG (2013). Infusion of endomorphin-1 (EM-1) in the MPOA and the Me modulate sexual and socio-sexual behavior in the male rat. *Brain Res* **1517**: 36-43.

Plein LM, Rittner HL (2017). Opioids and the immune system - friend or foe. *British journal of pharmacology*.

Puglisi-Allegra S, Oliverio A (1983). Social isolation: effects on pain threshold and stress-induced analgesia. *Pharmacol Biochem Behav* **19**(4): 679-681.

Pusponegoro HD, Ismael S, Sastroasmoro S, Firmansyah A, Vandenplas Y (2015). Maladaptive Behavior and Gastrointestinal Disorders in Children with Autism Spectrum Disorder. *Pediatr Gastroenterol Hepatol Nutr* **18**(4): 230-237.

Ragen BJ, Freeman SM, Laredo SA, Mendoza SP, Bales KL (2015a). mu and kappa opioid receptor distribution in the monogamous titi monkey (*Callicebus cupreus*): implications for social behavior and endocrine functioning. *Neuroscience* **290**: 421-434.

Ragen BJ, Maninger N, Mendoza SP, Bales KL (2015b). The effects of morphine, naloxone, and kappa opioid manipulation on endocrine functioning and social behavior in monogamous titi monkeys (*Callicebus cupreus*). *Neuroscience* **287**: 32-42.

Ragen BJ, Maninger N, Mendoza SP, Jarcho MR, Bales KL (2013). Presence of a pair-mate regulates the behavioral and physiological effects of opioid manipulation in the monogamous titi monkey (*Callicebus cupreus*). *Psychoneuroendocrinology* **38**(11): 2448-2461.

Reichelt KL, Knivsberg A-M, Lind G, Nødland M (1991). Probable etiology and possible treatment of childhood autism. *Brain Dysfunction* **4**(6): 308-319.

Reichelt KL, Tveiten D, Knivsberg AM, Bronstad G (2012). Peptides' role in autism with emphasis on exorphins. *Microb Ecol Health Dis* **23**.

Resendez SL, Dome M, Gormley G, Franco D, Nevarez N, Hamid AA, *et al.* (2013). mu-Opioid receptors within subregions of the striatum mediate pair bond formation through parallel yet distinct reward mechanisms. *J Neurosci* **33**(21): 9140-9149.

Richey JA, Rittenberg A, Hughes L, Damiano CR, Sabatino A, Miller S, *et al.* (2014). Common and distinct neural features of social and non-social reward processing in autism and social anxiety disorder. *Soc Cogn Affect Neurosci* **9**(3): 367-377.

Robinson SJ (2012). Childhood epilepsy and autism spectrum disorders: psychiatric problems, phenotypic expression, and anticonvulsants. *Neuropsychology review* **22**(3): 271-279.

Rodriguez-Arias M, Navarrete F, Blanco-Gandia MC, Arenas MC, Bartoll-Andres A, Aguilar MA, *et al.* (2016). Social defeat in adolescent mice increases vulnerability to alcohol consumption. *Addict Biol* **21**(1): 87-97.

Ross DL, Klykylo WM, Hitzemann R (1987). Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. *Pediatr Neurol* **3**(2): 83-86.

Roughgarden J (2012). The social selection alternative to sexual selection. *Philos Trans R Soc Lond B Biol Sci* **367**(1600): 2294-2303.

Rovee-Collier C (1999). The development of Infant Memory. *Current Directions in Psychological Science* **8**(3): 80-85.

Roy A, Roy M, Deb S, Unwin G (2015). Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. *J Intellect Disabil Res* **59**(4): 293-306.

Roy S, Liu HC, Loh HH (1998). mu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit. *Brain research. Molecular brain research* **56**(1-2): 281-283.

Rubin BS, Bridges RS (1984). Disruption of ongoing maternal responsiveness in rats by central administration of morphine sulfate. *Brain Res* **307**(1-2): 91-97.

Samaco RC, Mandel-Brehm C, McGraw CM, Shaw CA, McGill BE, Zoghbi HY (2012). Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome. *Nat Genet* **44**(2): 206-211.

Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D, *et al.* (2011). Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. *Neuron* **70**(5): 863-885.

Sasson NJ, Dichter GS, Bodfish JW (2012). Affective responses by adults with autism are reduced to social images but elevated to images related to circumscribed interests. *PLoS One* **7**(8): e42457.

Schino G, Troisi A (1992). Opiate receptor blockade in juvenile macaques: effect on affiliative interactions with their mothers and group companions. *Brain Res* **576**(1): 125-130.

Scott-Van Zeeland AA, Dapretto M, Ghahremani DG, Poldrack RA, Bookheimer SY (2010). Reward processing in autism. *Autism Res* **3**(2): 53-67.

Sepeta L, Tsuchiya N, Davies MS, Sigman M, Bookheimer SY, Dapretto M (2012). Abnormal social reward processing in autism as indexed by pupillary responses to happy faces. *J Neurodev Disord* **4**(1): 17.

Shapiro LE, Meyer ME, Dewsbury DA (1989). Affiliative behavior in voles: effects of morphine, naloxone, and cross-fostering. *Physiol Behav* **46**(4): 719-723.

Shattock P, Hooper M, Waring R (2004). Opioid peptides and dipeptidyl peptidase in autism. *Dev Med Child Neurol* **46**(5): 357; author reply 357-358.

Shi J, Li SX, Zhang XL, Wang X, Le Foll B, Zhang XY, *et al.* (2009). Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts. *Am J Drug Alcohol Abuse* **35**(5): 267-272.

Sia AT, Lim Y, Lim EC, Goh RW, Law HY, Landau R, *et al.* (2008). A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. *Anesthesiology* **109**(3): 520-526.

Slavich GM, Tartter MA, Brennan PA, Hammen C (2014). Endogenous opioid system influences depressive reactions to socially painful targeted rejection life events. *Psychoneuroendocrinology* **49**: 141-149.

Smith CJ, Wilkins KB, Mogavero JN, Veenema AH (2015). Social Novelty Investigation in the Juvenile Rat: Modulation by the mu-Opioid System. *J Neuroendocrinol* **27**(10): 752-764.

Sobczak M, Salaga M, Storr MA, Fichna J (2014). Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. *J Gastroenterol* **49**(1): 24-45.

Sokolov O, Kost N, Andreeva O, Korneeva E, Meshavkin V, Tarakanova Y, *et al.* (2014). Autistic children display elevated urine levels of bovine casomorphin-7 immunoreactivity. *Peptides* **56**: 68-71.

Solaas KM, Skjeldal O, Gardner ML, Kase FB, Reichelt KL (2002). Urinary peptides in Rett syndrome. *Autism* **6**(3): 315-328.

Solomon M, Frank MJ, Ragland JD, Smith AC, Niendam TA, Lesh TA, *et al.* (2015). Feedback-driven trial-by-trial learning in autism spectrum disorders. *Am J Psychiatry* **172**(2): 173-181.

South M, Chamberlain PD, Wigham S, Newton T, Le Couteur A, McConachie H, *et al.* (2014). Enhanced decision making and risk avoidance in high-functioning autism spectrum disorder. *Neuropsychology* **28**(2): 222-228.

Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, *et al.* (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. *Nucleic Acids Res* **44**(D1): D1054-1068.

Stavropoulos KK, Carver LJ (2014). Reward anticipation and processing of social versus nonsocial stimuli in children with and without autism spectrum disorders. *J Child Psychol Psychiatry* **55**(12): 1398-1408.

Syal S, Ipser J, Terburg D, Solms M, Panksepp J, Malcolm-Smith S, *et al.* (2015). Improved memory for reward cues following acute buprenorphine administration in humans. *Psychoneuroendocrinology* **53**: 10-15.

Takahashi A, Quadros IM, de Almeida RM, Miczek KA (2012). Behavioral and pharmacogenetics of aggressive behavior. *Curr Top Behav Neurosci* **12**: 73-138.

Tordjman S, Anderson GM, Botbol M, Brailly-Tabard S, Perez-Diaz F, Graignic R, *et al.* (2009). Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder. *PLoS One* **4**(8): e5289.

Tordjman S, Anderson GM, McBride PA, Hertzog ME, Snow ME, Hall LM, *et al.* (1997). Plasma beta-endorphin, adrenocorticotropin hormone, and cortisol in autism. *J Child Psychol Psychiatry* **38**(6): 705-715.

Trezza V, Baarendse PJ, Vanderschuren LJ (2010). The pleasures of play: pharmacological insights into social reward mechanisms. *Trends in pharmacological sciences* **31**(10): 463-469.

Trezza V, Damsteegt R, Achterberg EJ, Vanderschuren LJ (2011). Nucleus accumbens mu-opioid receptors mediate social reward. *J Neurosci* **31**(17): 6362-6370.

Trezza V, Vanderschuren LJ (2008). Bidirectional cannabinoid modulation of social behavior in adolescent rats. *Psychopharmacology (Berl)* **197**(2): 217-227.

Troisi A, Frazzetto G, Carola V, Di Lorenzo G, Coviello M, D'Amato FR, *et al.* (2011). Social hedonic capacity is associated with the A118G polymorphism of the mu-opioid receptor gene (OPRM1) in adult healthy volunteers and psychiatric patients. *Soc Neurosci* **6**(1): 88-97.

Van den Berg CL, Van Ree JM, Spruijt BM, Kitchen I (1999). Effects of juvenile isolation and morphine treatment on social interactions and opioid receptors in adult rats: behavioural and autoradiographic studies. *Eur J Neurosci* **11**(9): 3023-3032.

Vanderschuren LJ, Achterberg EJ, Trezza V (2016). The neurobiology of social play and its rewarding value in rats. *Neurosci Biobehav Rev* **70**: 86-105.

Vanderschuren LJ, Niesink RJ, Spruijt BM, Van Ree JM (1995a). Effects of morphine on different aspects of social play in juvenile rats. *Psychopharmacology (Berl)* **117**(2): 225-231.

Vanderschuren LJ, Niesink RJ, Spruijt BM, Van Ree JM (1995b). Mu- and kappa-opioid receptor-mediated opioid effects on social play in juvenile rats. *Eur J Pharmacol* **276**(3): 257-266.

Vanderschuren LJ, Stein EA, Wiegant VM, Van Ree JM (1995c). Social play alters regional brain opioid receptor binding in juvenile rats. *Brain Res* **680**(1-2): 148-156.

Veenstra-VanderWeele J, Blakely RD (2012). Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments. *Neuropsychopharmacology* **37**(1): 196-212.

Watson KK, Miller S, Hannah E, Kovac M, Damiano CR, Sabatino-DiCrisco A, *et al.* (2015). Increased reward value of non-social stimuli in children and adolescents with autism. *Front Psychol* **6**: 1026.

Way BM, Taylor SE, Eisenberger NI (2009). Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. *Proc Natl Acad Sci U S A* **106**(35): 15079-15084.

Weizman R, Gil-Ad I, Dick J, Tyano S, Szekely GA, Laron Z (1988). Low plasma immunoreactive beta-endorphin levels in autism. *J Am Acad Child Adolesc Psychiatry* **27**(4): 430-433.

Weizman R, Weizman A, Tyano S, Szekely G, Weissman BA, Sarne Y (1984). Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects. *Psychopharmacology (Berl)* **82**(4): 368-370.

White SW, Kreiser NL, Pugliese C, Scarpa A (2012). Social anxiety mediates the effect of autism spectrum disorder characteristics on hostility in young adults. *Autism* **16**(5): 453-464.

Whyatt C, Craig C (2013). Sensory-motor problems in Autism. *Frontiers in integrative neuroscience* **7**: 51.

Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, Thijssen JH, Van Engeland H (1996). Plasma beta-endorphin concentrations in people with learning disability and self-injurious and/or autistic behaviour. *The British journal of psychiatry : the journal of mental science* **168**(1): 105-109.

Wohr M, Moles A, Schwarting RK, D'Amato FR (2011). Lack of social exploratory activation in male mu-opioid receptor KO mice in response to playback of female ultrasonic vocalizations. *Soc Neurosci* **6**(1): 76-87.

Yamanaka T, Sadikot RT (2013). Opioid effect on lungs. *Respirology* **18**(2): 255-262.

Yim AJ, Miranda-Paiva CM, Florio JC, Oliveira CA, Nasello AG, Felicio LF (2006). A comparative study of morphine treatment regimen prior to mating and during late pregnancy. *Brain Res Bull* **68**(5): 384-391.

Younger J, Aron A, Parke S, Chatterjee N, Mackey S (2010). Viewing pictures of a romantic partner reduces experimental pain: involvement of neural reward systems. *PLoS One* **5**(10): e13309.

Zanos P, Georgiou P, Wright SR, Hourani SM, Kitchen I, Winsky-Sommerer R, *et al.* (2014). The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice. *Neuropsychopharmacology* **39**(4): 855-865.

Accepted Article

Legends to figures




Figure 1. Effects of regional pharmacological manipulation of μ OR on social behaviour and regional μ OR expression in rodents (left panel) and humans (right panel) under social comfort (green) or social distress (black) conditions. Lateralisation of brain responses (right or left hemisphere) was not taken into account for simplification purpose. Pharmacological manipulations of μ OR and modifications in μ OR expression (in rodents) or availability (humans) affect similar brain regions, independently from the social context. These structures mostly belong to the reward circuitry (highlighted in orange). ACC: anterior cingulate cortex, AMG: amygdala, AOB: accessory olfactory bulb, BNST: bed nucleus of stria terminalis, CC: cingular cortex; CPu: caudate putamen, IC: insular cortex, GP: globus pallidus, LC, locus coeruleus, LS: lateral septum, MCC: middle cingulate cortex, NAc: nucleus accumbens, OFC: orbitofrontal cortex, PAG: periaqueductal gray matter, PCC: posterior cingulate cortex, PFC: medial prefrontal cortex, POA: preoptic area of hypothalamus, PVN: paraventricular nucleus of hypothalamus, Th: thalamus, VTA: ventral tegmental area.




Figure 2. The μ OR Balance Model. μ opioid receptor (μ OR) activity competes with Social Avoidance Systems (SAS) to drive social behaviours. In a narrow window of optimal functioning, μ OR activity is balanced with SAS to allow adaptive social behaviour. These conditions are ideal to detect social reward (good signal to noise ratio). On the left part of the curve, low μ OR activity, due to social distress, pharmacological antagonism or genetic anomaly, leads to reduced social reward and/or motivation and leaves the field clear for SAS to elicit social withdrawal (insufficient signal). On the right part of the curve, excessive μ OR activity, due to intense and/or prolonged exposure to opioid ligands or increased μ OR expression, saturates the reward system and produces social indifference (excessive noise). Importantly, in this model, blocking μ OR activity in the case of excessive tone, or stimulating μ OR when the tone is too low, can restore normal, adaptive, social behaviour.




Figure 3. Brain areas differentially activated in patients with ASD versus controls during social (left panel) or monetary (right panel) reward anticipation and/or processing. Lateralisation of brain responses (right or left hemisphere) was not taken into account for simplification purpose. Comparing brain activation patterns for social and monetary reward reveals common hypoactivation of a frontostriatal circuit including key regions for reward processing that are ACC, NAc and CPU in patients with ASD. The nature of stimuli used for experiments (images of faces, verbal praise, social reinforcement), tasks performed (stimulus presentation versus game or learning task for example) and timing (anticipation versus reward processing) varied across studies, possibly accounting for discrepancies in the level of activation of some structures (IC, AMG, OFC). Brain regions belonging to the reward circuitry are highlighted in orange. ACC: anterior cingulate cortex, AMG: amygdala, CPU: caudate putamen, dACC: dorsal anterior cingulate cortex, dIPFC: dorsolateral prefrontal cortex, HPC/EC: hippocampus/enthorinal cortex, IC: insular cortex, MB: midbrain, MFG: medial frontal gyrus, NAc: nucleus accumbens, OFC: orbitofrontal cortex, paraCC: paracingulate cortex, PC: parietal cortex, pCC: posterior cingulate cortex, PCG: precentral gyrus, PG: parahippocampal gyrus, SFG: superior frontal gyrus, STG: superior temporal gyrus, vPFC: ventral prefrontal cortex.




Figure 4. Copy number variation in the *OPRM1* gene of patients with autism spectrum disorders (ASD). *OPRM1* is located on chromosome 6 at the q25.2 position. The map was built based on the integrated catalogue of copy number variants associated with ASD from the Simons Foundation Autism Research Initiative (SFARI) resource website (<https://gene.sfari.org/autdb/CNVHome.do>; September 2016). We identified 10 patients from this database displaying CNVs that affect the *OPRM1* gene (8 deletions, 2 duplications) (Battaglia *et al.*, 2013; Halgren *et al.*, 2012; Kaminsky *et al.*, 2011; Sanders *et al.*, 2011). No CNVs were detected in controls, some of which bearing mutations immediately beyond *OPRM1* boundaries. Remarkably, *OPRM1* CNVs were all detected in low functioning ASD subjects (with intellectual disability). ID: intellectual deficiency, IQ: intellectual quotient.

Legends to tables

Table 1. Effects of pharmacological manipulation of μ OR on social behaviour.

Species	Age	Housing	Drug	Dose	Route	Treatment schedule	Effects on social behaviour	References
Social distress								
<i>Agonists</i>								
Mouse	Young adults	Isolated 3 weeks	Morphine	+ /+++	Systemic	Acute	Decreased timid/defensive behaviour in females	Benton <i>et al.</i> , 1985
Rat	Pups	Isolated from mother	DAMGO	+	Intracisternal	Acute	Reduced USVs at all doses	Carden <i>et al.</i> , 1991
Rat	Juveniles	Isolated from weaning	Morphine	+	Systemic	Acute	Increased pinning in social play	Panksepp <i>et al.</i> , 1979
Rat	Juveniles	Isolated from weaning	Morphine	+	Systemic	Acute	Increased social dominance slightly	Panksepp <i>et al.</i> , 1985
Rat	Juveniles	Isolated from weaning	Morphine	+	Systemic	Acute	Increased wanting to play	Normansell <i>et al.</i> , 1990
Rat	Juveniles	Isolated from weaning	Morphine	+	Systemic	Chronic	Restored social exploration and contact	Van den Berg <i>et al.</i> , 1999
Rat	Juveniles	Isolated 3.5h	Fentanyl	+	Systemic	Acute	Increased social play	Vanderschuren <i>et al.</i> , 1995b
Rat	Juveniles	Isolated 3.5h	Morphine	+	Systemic	Acute	increased social play	Vanderschuren <i>et al.</i> , 1995a
Rat	Juveniles	Isolated 3.5h	Morphine	+	Systemic	Acute	Increased social play in an unfamiliar environment	Trezza <i>et al.</i> , 2008
Rat	Juveniles	Isolated 2h	Morphine, DAMGO	+	NAc	Acute	Increased social play	Trezza <i>et al.</i> , 2011
Rat	Juveniles	Isolated 2h	Beta-endorphin, Met-enkephalin	+	NAc	Acute	Increased social play	
Rat	Young adults	Isolated and defeated	DAMGO	+	VTA	2 times	Decreased defeat-induced inactivity	Nikulina <i>et al.</i> , 2005
Rat	Young adults	Isolated from weaning, defeated	Morphine	+ /+++	PAG ventrolateral	Acute	Decreased defeat-induced USVs	Vivian <i>et al.</i> , 1998
Macaque	Infants	Isolated from mother	Morphine	+	Systemic	3 times	Reduced USVs and isolation-induced inactivity	Kalin <i>et al.</i> , 1988
Macaque	Infants	Chronic separation with mother	Morphine	+	Systemic	Acute	Increased mother-infants clinging	Kalin <i>et al.</i> , 1995
Marmoset	Juveniles	Transparent physical separation	Morphine	+/-	Systemic	Acute	Increased social play	Guard <i>et al.</i> , 2002
Titi monkey	Young adults	30 min isolation	Morphine	+	Systemic	Acute	Increased affiliative behaviour in males and decreased female breaks	Ragen <i>et al.</i> , 2015b
							Trend for reduced male approaches and reduced number of males initiating contact with pair-mate	
<i>Antagonists</i>								
Mouse	Young adults	Isolated from weaning	Naloxone	++	Systemic	Acute	Increased fearful/defensive postures when exposed to resident mouse	Brain <i>et al.</i> , 1985

Rat	Juveniles	Isolated 3.5h	β -funaltrexamine	+	Systemic	Acute	Decreased social play	Vanderschuren <i>et al.</i> , 1995b
Rat	Juveniles	Isolated from weaning	Naloxone	+	Systemic	Acute	Decreased pinning in social play	Panksepp <i>et al.</i> , 1979
Rat	Juveniles	Isolated from weaning	Naloxone	+	Systemic	Acute	Decreased wanting to play	Normansell <i>et al.</i> , 1990
Rat	Juveniles	Isolated from weaning	Naloxone	+	Systemic	Acute	Decreased social dominance	Panksepp <i>et al.</i> , 1985
Rat	Juveniles	Isolated 8 days	CTAP	+	NAc	Acute	Decreased social play	Trezza <i>et al.</i> , 2011
Rat	Young adults	Isolated and defeated	Naloxone	+	Systemic	Acute	Increased defeat-induced chewing/teeth chattering and shakes	Chaijale <i>et al.</i> , 2013
Macaque	Infants	Isolated from mother	Naloxone	+	Systemic	3 times	Increased USVs	Kalin <i>et al.</i> , 1988
Macaque	Infants	Chronic separation with mother	Naltrexone	+	Systemic	Acute	Reduced mother-infants clinging	Kalin <i>et al.</i> , 1995
Titi monkey	Young adults	30 min isolation	Naloxone	+	Systemic	Acute	Increased female breaks	Ragen <i>et al.</i> , 2015b
Social comfort								
<i>Agonists</i>								
Rat	Young adults	Groups	Morphine	+	Systemic	Acute	Enhanced social recognition memory	Bianchi <i>et al.</i> , 2013
Rat	Young adults	Groups	Heroin	+ / ++	Systemic	Acute/pre-treatment	Enhanced social recognition memory	Levy <i>et al.</i> , 2009
Rat	Young males	Isolated with females	Endomorphin-1	+	Medial POA	Acute	Increased mount and pursuit duration	Parra-Gómez <i>et al.</i> , 2013
			Endomorphin-1	+	Medial amygdala	Acute	Increased mount number and ejaculation latency	
Human	Young adults		Buprenorphine	+	Systemic	Acute	Increased ratings of images with social context	Bershad <i>et al.</i> 2016
							Reduced attention to fear expressions and perceived social rejection	
Human	Young adults		Buprenorphine	+	Systemic	Acute	Improved short term memory for happy expressions	Syal <i>et al.</i> , 2015
Human	Young men		Remifentanil	+	Systemic	Acute	Increased rating of pleasantness for neutral pictures	Gospic <i>et al.</i> , 2007
Human	Young men		Morphine		Systemic	3 days	Increased 'keep' presses for the most attractive female faces	Chelnokova <i>et al.</i> , 2014
<i>Antagonists</i>								
Mouse	Pups	Groups	Naltrexone	+	Systemic	4 first days postnatal	Abolished preference for own cage and own mother in pups	Cinque <i>et al.</i> , 2012
							Abolished congener preference and social place preference in adults	
Mouse KI Oprm1 ^{A112G}	Adults	Groups	Naloxone	+	Systemic	Acute	Abolished preference for congener in the three-chamber test	Briand <i>et al.</i> , 2015
Rat	Juveniles	Groups	CTAP	+	Lateral ventricle	Acute	Reduced social investigation time	Smith <i>et al.</i> , 2015
Prairie vole	Adult females	Isolated with males	Naltrexone	++	Systemic	Acute	Reduced mating bouts and suppressed partner preference	Burkett <i>et al.</i> , 2011
			Naltrexone	++	Systemic	3 times	Reversed preference for stranger versus partner	
			CTAP	++	NAc	Acute	No effect on partner preference	

			CTAP	++	CPu	Acute	Suppressed partner preference	
Prairie vole	Adult females	Isolated with males	CTAP	++	CPu	Acute	Suppressed partner preference and mating bouts	Resendez <i>et al.</i> , 2013
			CTAP	++	NAc core	Acute	No effect on partner preference and decreased mating bouts	
			CTAP	++	NAc dorsomedial shell	Acute	Suppressed partner preference and no effect on mating bouts	
			CTAP	++	NAc ventral shell	Acute	No effect on partner preference and mating bouts	
Macaque	Juveniles	Stable social group	Naloxone	+	Systemic	Acute	Increased proximity with mothers and demands for comfort	Schino <i>et al.</i> , 1992
Titi monkey	Young adults	Groups	Naloxone	+	Systemic	Acute	Reduced grooming and male approach	Ragen <i>et al.</i> , 2013
Titi monkey	Young adults	Groups	Naloxone	+	Systemic	Acute	Increased female breaks	Ragen <i>et al.</i> , 2015b
Human	Young adults		Naltrexone	+	Systemic	Acute	Increased negative emotions muscle responses to happy faces	Meier <i>et al.</i> , 2016
Human	Young adults		Naltrexone	+	Systemic	4 times	Reduced feeling of social connections	Inagaki <i>et al.</i> , 2016
Human	Young adults		Naltrexone	+	Systemic	4 times	Decreased female face attractiveness	Chelnokova <i>et al.</i> , 2014
Excessive opioid stimulation								
Mouse	Young adults	Groups	Morphine	+++	Systemic	6 days, escalating	Reduced social interaction after 4-week abstinence	Goeldner <i>et al.</i> , 2008
Mouse	Young adults	Groups	Heroin	+++	Systemic	6 days, escalating	Reduced social interaction after 4- and 7-week abstinence	Lutz <i>et al.</i> , 2014
Mouse	Young adults	Isolated from weaning	Morphine	+++	Systemic	6 days, escalating	Reduced social interaction after 7-day abstinence	Zanos <i>et al.</i> , 2014
Mouse	Young adults	Groups	Morphine	+++	Systemic	6 days, escalating	Reduced social interaction and social preference in three-chamber test after 4-week abstinence	Becker <i>et al.</i> , 2016
Rat	Young adults	Groups	Morphine	++/+++	Systemic	Acute	Decreased social recognition memory	Bianchi <i>et al.</i> , 2013
Rat	Young adults	Groups	Morphine	+	Systemic	Chronic	Reduced social exploration	Van den Berg <i>et al.</i> , 1999
Rat	Nullipares or lactating females	Isolated from weaning	Morphine	++	Dorsal POA	Acute	Decreased care for pups	Rubin <i>et al.</i> , 1984
Rat	Juveniles	Isolated 3.5h	Morphine	++	Systemic	Acute	Decreased social play	Vanderschuren <i>et al.</i> , 1995a
Rat	Neonates	Females with their litters	Morphine	++	Systemic	23 days, escalating	Lag in development of social behaviours	Najam <i>et al.</i> , 1989
Rat	Young adults	Females with their litters	Morphine	+++	Systemic	Chronic	Increased latencies for full maternal behaviour	Miranda-Paiva <i>et al.</i> , 2001
Rat	Young adults	Females with their litters	Morphine	++	Systemic	Chronic	Increased latencies for full maternal behaviour	Miranda-Paiva <i>et al.</i> , 2003
Rat	Young adults	Females with their litters	Morphine	+++	Systemic	Chronic	Disrupted maternal behaviour	Yim <i>et al.</i> , 2006
Prairie vole	Young adults	Isolated one week	Morphine	+++	Systemic	Acute	Reduced huddling duration	Shapiro <i>et al.</i> , 1989
Titi monkey	Young adults	Groups, with pair mates	Morphine	+	Systemic	Chronic, 7 days	Reduced grooming, tendency towards reduced contact	Ragen <i>et al.</i> , 2013

CPu: caudate putamen, CTAP: D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH₂; DAMGO: [D-Ala², N-MePhe⁴, Gly-ol]-enkephalin, KI: knock-in, NAc: nucleus accumbens, POA: preoptic area of hypothalamus, USV: ultrasonic vocalisation, VTA: ventral tegmental area.

References: (Becker *et al.*, in press; Benton *et al.*, 1985; Bershad *et al.*, 2016; Bianchi *et al.*, 2013; Briand *et al.*, 2015; Burkett *et al.*, 2011; Carden *et al.*, 1991; Chaijale *et al.*, 2013; Chelnokova *et al.*, 2014; Cinque *et al.*, 2012; Genazzani *et al.*, 1989; Goeldner *et al.*, 2011; Gospic *et al.*, 2008; Guard *et al.*, 2002; Inagaki *et al.*, 2016b; Kalin *et al.*, 1988; Kalin *et al.*, 1995; Levy *et al.*, 2009; Lutz *et al.*, 2014; Meier *et al.*, 2016; Miranda-Paiva *et al.*, 2001; Miranda-Paiva *et al.*, 2003; Nikulina *et al.*, 2005; Normansell *et al.*, 1990; Panksepp, 1979; Panksepp *et al.*, 1985; Parra-Gamez *et al.*, 2013; Ragen *et al.*, 2015b; Ragen *et al.*, 2013; Resendez *et al.*, 2013; Rubin *et al.*, 1984; Schino *et al.*, 1992; Shapiro *et al.*, 1989; Smith *et al.*, 2015; Syal *et al.*, 2015; Trezza *et al.*, 2011; Trezza *et al.*, 2008; Van den Berg *et al.*, 1999; Vanderschuren *et al.*, 1995a; Vanderschuren *et al.*, 1995b; Yim *et al.*, 2006; Zanos *et al.*, 2014).

Accepted Article

Table 2. Dosage of blood, CSF or urinary opioid peptides in subjects with ASD or Rett Syndrome.

Opioid peptide	Fluid	Detection method	Number of subjects	Results	References
β -Endorphin	Plasma	RIA	13	Similar in ASD and controls	Ernst <i>et al.</i> , 1993
β -Endorphin	Plasma	RIA	10	Decreased in ASD compared to controls	Weizman <i>et al.</i> , 1984
β -Endorphin	Plasma	RIA	22	Decreased in ASD compared to controls	Weizman <i>et al.</i> , 1988
β -Endorphin	Plasma	RIA	67	Increased in ASD compared to controls	Leboyer <i>et al.</i> , 1994
			22	Increased in Rett Syndrome compared to controls	
β -Endorphin	Plasma	RIA	62	Increased in mothers of children with ASD compared to controls	Leboyer <i>et al.</i> , 1999
β -Endorphin	Plasma	RIA	10	Increased in ASD compared to controls	Bouvard <i>et al.</i> , 1995
β -Endorphin	Plasma	RIA	33	Increased in ASD compared to controls	Willemsen-Swinkels <i>et al.</i> , 1996
β -Endorphin	Plasma	RIA	48	Increased in ASD compared to controls	Tordjman <i>et al.</i> , 1997
β -Endorphin	Plasma	RIA	12	Increased in ASD compared to controls	Brambilla <i>et al.</i> , 1997
β -Endorphin	Plasma	RIA	11	Increased in ASD compared to controls	Cazzullo <i>et al.</i> , 1999
β -Endorphin	Plasma	RIA	73	Increased in ASD compared to controls	Tordjman <i>et al.</i> , 2009
β -Endorphin	CSF	RIA	19	Similar in ASD and controls	Nagamitsu <i>et al.</i> , 1993
β -Endorphin			3	Increased in Rett Syndrome compared to controls	
β -Endorphin	CSF	RIA	22	Similar in ASD and controls	Nagamitsu <i>et al.</i> , 1997
β -Endorphin	CSF	RIA	9	Decreased in Rett Syndrome compared to controls	Genazzani <i>et al.</i> , 1989
β -Endorphin	CSF	RIA	31	Decreased in ASD compared to controls	Gillberg <i>et al.</i> , 1990
β -Endorphin			8	Decreased in Rett Syndrome compared to controls	
β -Endorphin	CSF	RIA	9	Increased in ASD compared to controls	Ross <i>et al.</i> , 1987
Met-Enkephalin	CSF	RIA	24	Increased in ASD compared to controls	Gillberg <i>et al.</i> , 1985
Opioid Peptides	Urine	HPLC	54	Not detected	Dettmer <i>et al.</i> , 2007
Opioid Peptides	Urine	Mass Spec	10	Not detected	Shattock <i>et al.</i> , 2004
Opioid Peptides	Urine	HPLC	97	Not detected	Pusponegoro <i>et al.</i> , 2015
Opioid Peptides	Urine	Mass Spec	65	Similar in ASD and controls	Cass <i>et al.</i> , 2008
β -Casomorphin	Urine	ELISA	10	Increased in ASD compared to controls	Sokolov <i>et al.</i> , 2014
β -Casomorphin	Urine	HPLC	53	Increased in Rett Syndrome compared to controls	Solaas <i>et al.</i> , 2002
			35	Increased in ASD compared to controls	
Exorphins	Urine	HPLC	135	Increased in ASD compared to controls	Reichelt <i>et al.</i> , 2012

CSF: cerebrospinal fluid, RIA: radioimmunoassay, HPLC: high performance liquid chromatography, Mass Spec: Mass Spectrometry, ASD: Autism Spectrum Disorders.

References: (Bouvard *et al.*, 1995; Brambilla *et al.*, 1997; Cass *et al.*, 2008; Cazzullo *et al.*, 1999; Dettmer *et al.*, 2007; Ernst *et al.*, 1993; Gillberg *et al.*, 1990; Gillberg *et al.*, 1985; Leboyer *et al.*, 1994; Leboyer *et al.*, 1999; Nagamitsu, 1993; Nagamitsu *et al.*, 1997; Pusponegoro *et al.*, 2015; Reichelt *et al.*, 2012; Ross *et al.*, 1987; Shattock *et al.*, 2004; Sokolov *et al.*, 2014; Solaas *et al.*, 2002; Tordjman *et al.*, 2009; Tordjman *et al.*, 1997; Weizman *et al.*, 1988; Weizman *et al.*, 1984; Willemsen-Swinkels *et al.*, 1996)